Mediation of adenylyl cyclase sensitization by PTX-insensitive GαoA, Gαi1, Gαi2 or Gαi3

Journal of Neurochemistry

Volumn 99, Issue 6, 2006, Pages 1494-1504

  Clark, Mary J ^b   Traynor, John R ^a,b  

^a 1301 MSRB III ^*  (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Adenylyl cyclase; cAMP overshoot; G i o subtypes; Mu opioid; Pertussis toxin; Sensitization

Indexed keywords

ADENYLATE CYCLASE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ISOLEUCINE; ISOPROTEIN; MU OPIATE RECEPTOR; PERTUSSIS TOXIN; PROTEIN SUBUNIT;

ANIMAL CELL; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; ENZYME ACTIVITY; GENETIC TRANSFECTION; GLIOMA CELL; HUMAN; HUMAN CELL; INHIBITION KINETICS; MOLECULAR CLONING; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIZATION; SERUM;

1-METHYL-3-ISOBUTYLXANTHINE; ADENYLATE CYCLASE; ANALGESICS, OPIOID; BLOTTING, WESTERN; CELL LINE; CYCLIC AMP; CYSTEINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; FORSKOLIN; GENE EXPRESSION; GLIOMA; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; HUMANS; MUTATION; PERTUSSIS TOXIN; PHOSPHODIESTERASE INHIBITORS; RECEPTORS, OPIOID, MU; TIME FACTORS; TRANSFECTION;

BOS TAURUS;

EID: 33845526006     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2006.04176.x     Document Type: Article

References (48)

1. Albasanz J. L., Ros M. and Martin M. (1997) Characterization of metabotropic glutamate receptors in rat C6 glioma cells. Eur. J. Pharmacol. 326, 85-91.
2. Ammer H. and Christ T. E. (2002) Identity of adenylyl cyclase isoform determines the G protein mediating chronic opioid-induced adenylyl cyclase supersensitivity. J. Neurochem. 83, 818-827.
3. Avidor-Reiss T., Nevo I., Levy R., Pfeuffer T. and Vogel Z. (1996) Chronic opioid treatment induces adenylyl cyclase V superactivation. J. Biol. Chem. 271, 21 309-21 315.
4. Avidor-Reiss T., Nevo I., Saya D., Bayewitch M. and Vogel Z. (1997) Opiate-induced adenylyl cyclase superactivation is isozyme-specific. J. Biol. Chem. 272, 5040-5047.
5. 2A-adrenoceptor. Biochemistry 37, 11 555-11 562.
6. 2L dopamine receptor-mediated sensitization of adenylate cyclase type 6. Cell. Signalling 17, 647-653.
7. Beazely M. A., Alan J. K. and Watts V. J. (2005) Protein kinase C and epidermal growth factor stimulation of raf-1 potentiates adenylyl cyclase type 6 activation in intact cells. Mol. Pharmacol. 67, 250-259.
8. Belcheva M. M., Szùcs M., Wang D., Sadee W. and Coscia C. J. (2001) μ-Opioid receptor-mediated ERK activation involves calmodulin-dependent epidermal growth factor receptor transactivation. J. Biol. Chem. 276, 33 847-33 853.
9. Belcheva M. M., Haas P. D., Tan Y., Heaton V. M. and Coscia C. J. (2002) The fibroblast growth factor receptor is at the site of convergence between μ-opioid receptor and growth factor signaling pathways in rat C6 glioma cells. J. Pharmacol. Exp. Ther. 303, 909-918.
10. Bohn L. M., Galnetdinov R. R., Lin F.-T., Lefkowitz R. J. and Caron M. G. (2000) μ-Opioid receptor desensitization by β-arrestin-2 determines morphine tolerance but not dependence. Nature 408, 720-723.
11. Cechin S. R., Dunkley P. R. and Rodnight R. (2005) Signal transduction mechanism involved in the proliferation of C6 glioma cells induced by lysophosphatic acid. Neurochem. Res. 30, 603-611.
12. Chernausek S. D. (1993) Insulin-like growth factor-1 (IGF-1) production by astroglial cells: regulation and importance for epidermal growth factor-induced cell replication. J. Neurosci. Res. 34, 189-197.
13. o. Effects of adenylyl cyclase, extracellular signal-regulated kinases, and intracellular calcium pathways. J. Biol. Chem. 278, 9418-9425.
14. o-dependent, μ-opioid agonist-mediated adenylyl cyclase supersensitization. J. Pharmacol. Exp. Ther. 310, 215-222.
15. Clark M. J., Furman C. A., Gilson T. D. and Traynor J. R. (2006) Comparison of the relative efficacy and potency of μ-opioid agonists to activate Gαi/o proteins containing a pertussis toxin-insensitive mutation. J. Pharmacol. Exp. Ther. 317, 858-864.
16. 2 dopamine receptors. J. Pharmacol. Exp. Ther. 297, 1201-1209.
17. Debernardi M. A., Munshi R., Yoshimura M., Cooper D. M. F. and Brooker G. (1993) Predominant expression of type-VI adenylate cyclase in C6-2B rat glioma cells may account for inhibition of cyclic AMP accumulation by calcium. Biochem. J. 293, 325-328.
18. Della Rocca G. J., van Biesen T., Daaka Y., Luttrell D. K., Luttrell L. M. and Lefkowitz R. J. (1997) Ras-dependent mitogen-activated protein kinase activation by G protein-coupled receptors. J. Biol. Chem. 272, 19 125-19 132.
19. 2A receptor-activated cascade in rat C6 glioma cells. Neuroscience 69, 1119-1131.
20. Gerhardt M. A. and Neubig R. R. (1991) Multiple Gi protein subtypes regulate a single effector mechanism. Mol. Pharmacol. 40, 707-711.
21. Ghahremani M. H., Cheng P., Lembo P. M. and Albert P. R. (1999) Distinct roles for Gαi2, Gαi3, and Gβγ in modulation of forskolinor Gs-mediated cAMP accumulation and calcium mobilization by dopamine D2S receptors. J. Biol. Chem. 274, 9238-9245.
22. Hamel W. and Westphal M. (2000) Growth factors in gliomas revisited. Acta Neurochir. 142, 113-137.
23. 2L cells. J. Neurochem. 82, 1087-1096.
24. Lee K. O., Akil H., Woods J. H. and Traynor J. R. (1999) Differential binding properties of oripavines at cloned mu- and delta-opioid receptors. Eur. J. Pharmacol. 378, 323-330.
25. Moulédous L., Neasta J., Uttenweiler-Joseph S., Stells A., Matondo M., Corbani M., Monsarrat B. and Meunier J.-C. (2005) Long-term morphine treatment enhances proteasome-dependent degradation of Gβ in human neuroblastoma SH-SY5Y cells: correlation with onset of adenylyl cyclase sensitization. Mol. Pharmacol. 68, 467-476.
26. q subinits. Jpn J. Pharmacol. 81, 353-361.
27. o proteins in modulation of adenylyl cyclase type-2 activity. J. Neurochem. 83, 1252-1261.
28. Nevo I., Avidor-Reiss T., Levy R., Bayewitch M., Heldman E. and Vogel Z. (1998) Regulation of adenylyl cyclases isozymes on acute and chronic activation of inhibitory receptors. Mol. Pharmacol. 54, 419-426.
29. Nevo I., Avidor-Reiss T., Levy R. I., Bayewitch M. and Vogel Z. (2000) Acute and chronic activation of the μ-opioid receptor with the endogenous ligand endomorphin differentially regulates adenylyl cylcase isozymes. Neuropharmacology 39, 364-371.
30. Okumura N., Takimoto K., Okada M. and Nakagawa H. (1989) C6 glioma cells produce basic fibroblast growth factor that can stimulate their own proliferation. J. Biochem. 106, 904-909.
31. Rau T., Nose M., Remmers U., Weil J., Weissmüller A., Davia K., Harding S., Peppel K., Koch W. J. and Eschenhagen T. (2003) Overexpression of wild-type Gαi-2 suppresses β-adrenergic signaling in cardiac myocytes. FASEB J. 17, 523-525.
32. Rhee M.-H., Nevo I., Avidor-Reiss T., Levy R. and Vogel Z. (2000) Differential superactivation of adenylyl cyclase isozymes after chronic activation of the CB1 cannabinoid receptor. Mol. Pharmacol. 57, 746-752.
33. Rubenzik M., Varga E., Stropova D., Roeske W. R. and Yamamura H. I. (2001) Expression of α-transducin in Chinese Hamster Ovary cells stably transfected with the human δ-opioid receptor attenuates chronic opioid agonist-induced adenylyl cyclase superactivation. Mol. Pharmacol. 60, 1076-1082.
34. 2 cannabinoid receptor. Cancer Res. 61, 5784-5789.
35. Sharma S. K., Klee W. A. and Nirenberg M. (1975) Dual regulation of adenylyl cyclase accounts for narcotic dependence and tolerance. Proc. Natl Acad. Sci. USA 72, 3092-3096.
36. Tan C. M., Kelvin D. J., Litchfield D. W., Ferguson S. S. G. and Feldman R. D. (2001) Tyrosine kinase-mediated serine phosphorylation of adenylyl cyclase. Biochemistry 40, 1702-1709.
37. i2 in opioid-induced adenylyl cyclase supersensitization. Mol. Neurosci. 11, 3213-3217.
38. i3. Neurosci. Lett. 299, 25-28.
39. Valeins H., Merle M. and Labouesse J. (1992) Pre-steady state study of β-adrenergic and purinergic receptor interaction in C6 cell membranes: undelayed balance between positive and negative coupling to adenylyl cyclase. Mol. Pharmacol. 42, 1033-1041.
40. Varga E. V., Stropova D., Rubenzik M., Waite S., Roeske W. R. and Yamamura H. I. (1999) Phosphorylation of adenylyl cyclase VI upon chronic δ-opioid receptor stimulation. Eur. J. Pharmacol. 364, R1-R2.
41. Varga E. V., Rubenzik M. K., Grife V., Sugiyama M., Stropova D., Roeske W. R. and Yamamura H. I. (2002) Involvement of Raf-1 in chronic delta-opioid receptor agonist-mediated adneylyl cyclase superactivation. Eur. J. Pharmacol. 451, 101-103.
42. Varga E. V., Rubenzik M. K., Stropova D., Sugiyama M., Grife V., Hruby V. J., Rice K. C., Roeske W. R. and Yamamura H. I. (2003) Converging protein kinase pathways mediate adenylyl cyclase superactivation upon chronic δ-opioid agonist treatment. J. Pharmacol. Exp. Ther. 306, 109-115.
43. s in sensitization of AC1. Mol. Pharmacol. 66, 1617-1624.
44. Watts V. J. (2002) Molecular mechanisms for heterologous sensitization of adenylate cyclase. J. Pharmacol. Exp. Ther. 302, 1-7.
45. 2 dopamine receptors. Mol. Pharmacol. 50, 966-976.
46. 2L dopamine receptors in NS20Y neuroblastoma cells. J. Neurosci. 18, 8692-8699.
47. Yoshimura M., Wu P. H., Hoffman P. L. and Tabakoff B. (2000) Overexpression of type 7 adenylyl cyclase in the mouse brain enhances acute and chronic actions of morphine. Mol. Pharmacol. 58, 1011-1016.
48. Yue X., Varga E. V., Stropova D., Vanderah T. W., Yamamura H. I. and Roeske W. R. (2006) Chronic morphine-mediated adenylyl cyclase superactivation is attenuated by the raf-1 inhibitor, GW5074. Eur. J. Pharmacol. 540, 57-59.